Prolieve Thermodilatation System
Benign Prostatic Hyperplasia (BPH)
Key Facts
Indication
Benign Prostatic Hyperplasia (BPH)
Phase
Marketed
Status
Commercial / Phase 4 Post-Marketing
Company
About Medifocus
Medifocus Inc. is a public medical technology company with a mission to improve standards of care through its proprietary focused heat platforms. Its strategy leverages a revenue-generating, FDA-approved device for BPH (Prolieve®) to fund the clinical development of its late-stage Adaptive Phased Array (APA-1000) system for breast cancer. The company has established a robust intellectual property portfolio with approximately 100 patents and has secured regulatory approvals to initiate a pivotal Phase III trial for its oncology asset.
View full company profileOther Benign Prostatic Hyperplasia (BPH) Drugs
| Drug | Company | Phase |
|---|---|---|
| Optilume BPH Catheter System | Laborie | Commercial |
| RoLEP™ (Robotic-assisted HoLEP) | Andromeda Surgical | Unknown |
| Zenflow Procedure | Zenflow | Clinical Evaluation |
| TULSA-PRO® | Profound Medical | Commercial |
| Fexapotide Triflutate (NX-1207) | Nymox Pharmaceutical | Phase 3 |